{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06388122",
            "orgStudyIdInfo": {
                "id": "23-009689"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2024-03405",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trials Reporting Program)"
                },
                {
                    "id": "MC240301",
                    "type": "OTHER",
                    "domain": "Mayo Clinic"
                }
            ],
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "DiviTum\u00aeTKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients",
            "officialTitle": "DiviTum\u00aeTKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "divitum-tka-a-biomarker-assay-for-efficacy-in-hr-metastatic-breast-cancer-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-24",
            "studyFirstSubmitQcDate": "2024-04-26",
            "studyFirstPostDateStruct": {
                "date": "2024-04-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-07",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to explore the clinical utility of routinely measuring thymidine kinase activity (TKa) in HR+ metastatic breast cancer patients receiving treatment with any approved endocrine therapy either alone or in combination with any approved CDK4/6 inhibitor."
        },
        "conditionsModule": {
            "conditions": [
                "HER2-negative Breast Cancer",
                "Hormone-receptor-positive Breast Cancer",
                "Metastatic Breast Cancer"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group 1 (initiating 1st line CDK4/6 & endocrine therapy)",
                    "description": "Blood will be drawn every 14 days starting from the first treatment cycle until the start of cycle 3; starting at cycle 3 blood will be drawn the first day of every cycle thereafter until progression. Optional blood draws will be taken with standard of care labs when starting next therapy.",
                    "interventionNames": [
                        "Procedure: Biospecimen Collection"
                    ]
                },
                {
                    "label": "Group 2 (initiating 2nd or later line of CDK4/6 with or without endocrine therapy)",
                    "description": "Blood will be drawn every 14 days starting from the first treatment cycle until the start of cycle 3; starting at cycle 3 blood will be drawn the first day of every cycle thereafter until progression. Optional blood draws will be taken with standard of care labs when starting next therapy.",
                    "interventionNames": [
                        "Procedure: Biospecimen Collection"
                    ]
                },
                {
                    "label": "Group 3 (currently receiving 1st line CDK4/6 and endocrine therapy)",
                    "description": "Blood will be drawn on day 15 of the next cycle after enrollment and the first day of every cycle thereafter until progression. Optional blood draws will be taken with standard of care labs when starting next therapy.",
                    "interventionNames": [
                        "Procedure: Biospecimen Collection"
                    ]
                },
                {
                    "label": "Group 4 (initiating or currently receiving 1st or 2nd line endocrine therapy)",
                    "description": "Blood will be drawn at baseline or the first day of the treatment cycle and the first day of every cycle thereafter until progression. Optional blood draws will be taken with standard of care labs when starting next therapy.",
                    "interventionNames": [
                        "Procedure: Biospecimen Collection"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "PROCEDURE",
                    "name": "Biospecimen Collection",
                    "description": "Undergo blood sample collection",
                    "armGroupLabels": [
                        "Group 1 (initiating 1st line CDK4/6 & endocrine therapy)",
                        "Group 2 (initiating 2nd or later line of CDK4/6 with or without endocrine therapy)",
                        "Group 3 (currently receiving 1st line CDK4/6 and endocrine therapy)",
                        "Group 4 (initiating or currently receiving 1st or 2nd line endocrine therapy)"
                    ],
                    "otherNames": [
                        "Biological Sample Collection",
                        "Biospecimen Collected",
                        "Specimen Collection"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "DiviTum\u00aeTKa assay as an early predictor of primary treatment resistance",
                    "description": "Blood samples collected from participants will be assessed using DiviTum\u00aeTKa assay for thymidine kinase activity (TKa) levels above Limit of Detection (LOD) as a predictor of primary treatment resistance. Primary treatment resistance will be defined as disease progression in less than 6 months.",
                    "timeFrame": "Every cycle (approximately 28 days) until disease progression up to 6 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Pre- or post-menopausal HR+ metastatic breast cancer patients who are:\n\n  * Group 1: scheduled to initiate 1st line combination therapy with an FDA-approved CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) and an FDA-approved endocrine therapy for pre- or post-menopausal HR+ metastatic breast cancer (mBC).\n  * Group 2: scheduled to initiate second or later lines of therapy with an FDA-approved CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) with or without an FDA-approved endocrine therapy for pre- or post-menopausal HR+ mBC.\n  * Group 3: currently receiving 1st line therapy with an FDA-approved CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) and an FDA-approved endocrine therapy for pre- or post-menopausal HR+ mBC.\n  * Group 4: scheduled to initiate, or are currently receiving, 1st or 2nd line therapy of an FDA approved endocrine therapy (single agent) for pre- or post-menopausal HR+ mBC.\n\nNOTE: Patients that meet eligibility criteria for any of the above groups that are already enrolled in an ongoing clinical trial are eligible for co-enrollment to this observational study.\n\nExclusion Criteria:\n\n* Treatment including investigational agent or therapies\n* Early breast cancer diagnosis\n* Male breast cancer\n* Currently receiving treatment for other active malignancy at time of registration\n\n  * EXCEPTIONS: Nonmelanoma skin cancer or carcinoma-in-situ (e.g. of cervix, prostate)\n* Inability to give written informed consent",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Adult female patients \\> 18 years old with diagnosis of metastatic HR positive HER2 negative breast cancer that will be or are currently being treated with standard of care endocrine therapy +/- CDK 4/6 inhibitors.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trials Referral Office",
                    "role": "CONTACT",
                    "phone": "855-776-0015",
                    "email": "mayocliniccancerstudies@mayo.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Pooja Advani, MBBS, MD",
                    "affiliation": "Mayo Clinic",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic in Florida",
                    "status": "RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32224-9980",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials",
                            "role": "CONTACT",
                            "phone": "855-776-0015",
                            "email": "mayocliniccancerstudies@mayo.edu"
                        },
                        {
                            "name": "Pooja Advani, MBBS, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Mayo Clinic Clinical Trials",
                    "url": "https://www.mayo.edu/research/clinical-trials"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}